Hi Everyone - interesting article in the Australian on Tuesday 30th Aug. - Headed "Glaxo betting on HIV shake-up". Its disappointing that AVX has ceased its drug development programs but I understand that cost would be beyond our financial ability. I am not in any way a medical person but it does appear that what GSK are proposing is similar to what AVX were developing. They say that Glaxo's majority owned HIV business - ViiV- is starting the long process of proving that the use of an integrase inhibitor called dolute-gravir with their current HIV pill will reduce the current three drug routine to a two drug treatment which would be a game changer and produce fewer side effects. I have alerted AVX to the article but they are probably aware of it. I did suggest that there may be some opportunity to realise some value from the research already done by AVX. Time will tell.
AVX Price at posting:
3.8¢ Sentiment: Hold Disclosure: Held
